Ignite Creation Date:
2025-12-24 @ 1:58 PM
Ignite Modification Date:
2026-01-01 @ 4:19 PM
Study NCT ID:
NCT00334295
Status:
COMPLETED
Last Update Posted:
2012-07-31
First Post:
2006-06-05
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2002-12
Start Date Type:
None
Primary Completion Date:
2011-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2011-01
Completion Date Type:
ACTUAL
First Submit Date:
2006-06-05
First Submit QC Date:
None
Study First Post Date:
2006-06-07
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2012-01-11
Results First Submit QC Date:
None
Results First Post Date:
2012-07-31
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2012-06-11
Last Update Post Date:
2012-07-31
Last Update Post Date Type:
ESTIMATED